Truking Technology listed among China’s top 100 pharmaceutical enterprises
The 2022 China’s Pharmaceutical Industry Top 100 Enterprises List was released at the 2023 Conference on the Development of China’s Pharmaceutical Industry, Sansure Biotech Inc. and Truking Technology Limited in Changsha City made the list.
In 2022, the main business income of the top 100 enterprises accounted for 30.7% of the pharmaceutical industry, showing a slight decrease compared to 2021, but a significant increase compared to the 23% at the beginning of the 13th Five-Year Plan (2016-2020). The trend of steadily progress in industry concentration remains unchanged.
In addition, the threshold for the top 100 enterprises in 2022 has been raised to 3.39 billion yuan, an increase of 8% compared to the previous year, and the scale of top enterprises continues to increase.
Truking, which ranked 73rd on this list, has improved its ranking by 27 places compared to 2021.
As a leading enterprise in China’s pharmaceutical equipment industry and one of the well-known enterprises in the world’s pharmaceutical equipment industry, Truking has continuously made the list, reflecting its overall strength, innovation ability and social influence.
Truking achieved a revenue of 6.446 billion yuan in 2022, a year-on-year increase of 22.54%, and R&D investment reached 572 million yuan, a year-on-year increase of 17.16%.
Strong R&D investment has driven the rapid development of multiple technological fields, with a year-on-year growth rate of 171.25% in the bioengineering business.
Truking actively develops the biopharmaceutical and life science industry chain, further develops related industries in the biopharmaceutical field, extends the chain around life science fields such as biopharmaceutical consumables, high-end antibodies, and gene cell therapy, and continues to promote domestic substitution in the high-end equipment field, in a bid to promote good business performance and achieve vision goals.
Biopharmaceutical industry is a key industrial chain in Changsha. In March of this year, a three-year action plan for the development of Changsha’s bioeconomy (2023-2025) was issued, clarifying that by 2025, the scale of the city’s biopharmaceutical industry will exceed 200 billion yuan, and develop Changsha into a city of life and health with national competitiveness and international influence.
In 2022, the main business income of the top 100 enterprises accounted for 30.7% of the pharmaceutical industry, showing a slight decrease compared to 2021, but a significant increase compared to the 23% at the beginning of the 13th Five-Year Plan (2016-2020). The trend of steadily progress in industry concentration remains unchanged.
In addition, the threshold for the top 100 enterprises in 2022 has been raised to 3.39 billion yuan, an increase of 8% compared to the previous year, and the scale of top enterprises continues to increase.
Truking, which ranked 73rd on this list, has improved its ranking by 27 places compared to 2021.
As a leading enterprise in China’s pharmaceutical equipment industry and one of the well-known enterprises in the world’s pharmaceutical equipment industry, Truking has continuously made the list, reflecting its overall strength, innovation ability and social influence.
Truking achieved a revenue of 6.446 billion yuan in 2022, a year-on-year increase of 22.54%, and R&D investment reached 572 million yuan, a year-on-year increase of 17.16%.
Strong R&D investment has driven the rapid development of multiple technological fields, with a year-on-year growth rate of 171.25% in the bioengineering business.
Truking actively develops the biopharmaceutical and life science industry chain, further develops related industries in the biopharmaceutical field, extends the chain around life science fields such as biopharmaceutical consumables, high-end antibodies, and gene cell therapy, and continues to promote domestic substitution in the high-end equipment field, in a bid to promote good business performance and achieve vision goals.
Biopharmaceutical industry is a key industrial chain in Changsha. In March of this year, a three-year action plan for the development of Changsha’s bioeconomy (2023-2025) was issued, clarifying that by 2025, the scale of the city’s biopharmaceutical industry will exceed 200 billion yuan, and develop Changsha into a city of life and health with national competitiveness and international influence.
Ningxiang listed on China’s top 100 counties with comprehensive competitiveness 
College welcomes a student of courage 
Changsha Blue Moon Valley Intelligent Home Appliances Industrial Town 
This is Ningxiang High-tech Zone 
